News Press Releases

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Endo International plc Investors and Encourages Investors to Contact the Firm

December 5, 2016

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Endo International plc Investors and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Endo International plc (“Endo” or the “Company”) (NYSE: ENDP) securities between September 28, 2015 and November 2, 2016, inclusive (the “Class Period”). Endo investors have until January 6, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Endo investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

Bloomberg News has reported that the U.S. Justice Department may file a complaint against the Company and other alleged co-conspirators for fixing generic drug prices. The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.

On this news, Endo stock fell $6.25 per share, or nearly 27%, to close at $17.25 per share on November 3, 2016.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Endo’s subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to fix generic drug prices; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Endo’s revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Endo’s public statements were materially false and misleading at all relevant times.

If you purchased shares of Endo during the Class Period you may move the Court no later than January 6, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.